DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leader in innovative technology for medication delivery, today announced U.S. Food and Drug Administration (FDA) 510(k) ...
To date, there have been no reports of serious injury associated with this issue. Baxter International has issued an Urgent Medical Device Correction for the Novum IQ syringe infusion pump due to the ...
Baxter Canada, a leader in innovative technology for medication delivery, announced Health Canada marketing authorization of its new Novum IQ Infusion Platform. Building on the company's decades of ...
Baxter International Inc. announced today it has issued an Urgent Medical Device Correction for the Novum IQ syringe infusion pump. The Correction is due to the potential for an incomplete infusion ...
In the second quarter, Baxter turned in 1% operational sales growth and 28% adjusted EPS growth. Also, management reduced its guidance for 2025, including operational sales growth of 3% to 4% (down ...
Novum IQ Infusion Platform now offers large volume and syringe infusion smart pumps on an integrated system with shared innovative digital health solutions to help enhance patient safety and ...
Furthers Baxter’s continued innovation in medication delivery and management Integrates Baxter’s decades of leadership in infusion therapy with innovative digital health solutions to build on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results